Newsfile Corp
17 Jul 2026, 19:30 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Grail's NHS-Galleri trial failed to observe the primary endpoint of a statistically significant reduction in Stage III and IV cancers. — The failure of a primary clinical endpoint for a core product typically leads to a massive loss in valuation and confidence in the company's technology.
-0.90A federal securities class action lawsuit has been filed against Grail alleging that executives made false and misleading statements regarding the NHS-Galleri trial. — Class action lawsuits create significant legal overhang, potential financial liabilities, and damage corporate reputation.
-0.40Grail's common stock price experienced a one-day decline of approximately 50.55% following the trial result announcement on February 19, 2026. — While the price drop has already occurred, it confirms the extreme market sensitivity to the trial's failure.
-0.20Which stocks this story touches
Continue reading
6 related stories
Top 2 movers · tap to explore
The company is facing a federal securities class action lawsuit following a failed clinical trial and a subsequent 50% drop in stock price.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
1h ago
